Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of BCR::ABL1-negative ALL in Adults up to 65 Years
NCT07443592Not yet recruiting
- Sponsor
- Fundación PETHEMA
- Start
- Mar 2026
- Primary completion
- Mar 2031
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Open-label trial of blinatumomab in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Fundación PETHEMA. Primary endpoint: Overall Survival at 5 years. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07443592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07443592.